Clinical Chemistry:铁代谢、Hepcidin和心血管死亡率的关系?

2019-07-20 gladiator MedSci原创

贫血是冠心病(CAD)和死亡率的一个危险因素,而目前关于铁代谢对于其的作用仍有争议。 本研究分析了中位随访时间为9.9年的冠状动脉造影患者的铁代谢及其与心血管死亡和总死亡率的关系。在1480例冠心病稳定患者和682例经血管造影排除明显冠心病的患者中测定血红蛋白和铁水平。 研究结果显示,Multivariate-adjusted风险比率(小时)的总死亡率最低四分位数的铁、转铁蛋白饱和度、

贫血是冠心病(CAD)和死亡率的一个危险因素,而目前关于铁代谢对于其的作用仍有争议。

本研究分析了中位随访时间为9.9年的冠状动脉造影患者的铁代谢及其与心血管死亡和总死亡率的关系。在1480例冠心病稳定患者和682例经血管造影排除明显冠心病的患者中测定血红蛋白和铁水平。

研究结果显示,Multivariate-adjusted风险比率(小时)的总死亡率最低四分位数的铁、转铁蛋白饱和度、铁蛋白、可溶性转铁蛋白受体(血清)和血红蛋白分别为1.22 (95% CI, 0.96 - -1.60), 1.23(95%可信区间,0.97-1.56),1.27(95%可信区间,1.02 -1.58),1.26(95%可信区间,0.97 -1.65),0.99 (95% CI, 0.79 - -1.24)。最高四分位数的总死亡率对应的HRs分别为1.44 (95% CI, 1.10-1.87)1.37 (95% CI, 1.05-1.77)1.17 (95% CI, 0.92-1.50)1.76 (95% CI, 1.39-2.22)0.83 (95% CI, 0.63-1.09)心血管死亡的生命周期相似。对于hepcidin,校正后的总死亡率和心血管死亡的HRs分别为0.62 (95% CI, 0.49-0.78)0.70 (95% CI, 0.52-0.90),最高的四分位数与最低的四分位数相比。

研究表明,在接受血管造影的稳定患者中,血清铁、转铁蛋白饱和度、sTfR和铁蛋白呈j型相关,血红蛋白与心血管和总死亡率仅存在微弱的相关性。Hepcidin与死亡率呈负相关。

原始出处:

Tanja B. Grammer, Hubert Scharnagl,ron Metabolism, Hepcidin, and Mortality (the Ludwigshafen Risk and Cardiovascular Health Study)

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1752209, encodeId=60411e5220941, content=<a href='/topic/show?id=f2188e0859' target=_blank style='color:#2F92EE;'>#Hepcidin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8708, encryptionId=f2188e0859, topicName=Hepcidin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7a536471202, createdName=tm10051993, createdTime=Sat Oct 26 14:12:00 CST 2019, time=2019-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991612, encodeId=0258199161261, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Tue Jul 30 12:12:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783011, encodeId=ff891e83011c1, content=<a href='/topic/show?id=854546080a' target=_blank style='color:#2F92EE;'>#chemistry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4608, encryptionId=854546080a, topicName=chemistry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Thu May 21 20:12:00 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418494, encodeId=7bc5141849464, content=<a href='/topic/show?id=772e5182166' target=_blank style='color:#2F92EE;'>#心血管死亡率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51821, encryptionId=772e5182166, topicName=心血管死亡率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26613379061, createdName=smallant2003, createdTime=Mon Jul 22 14:12:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507032, encodeId=4f9d150e0321b, content=<a href='/topic/show?id=870c9653155' target=_blank style='color:#2F92EE;'>#铁代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96531, encryptionId=870c9653155, topicName=铁代谢)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d84f9850762, createdName=syscxl, createdTime=Mon Jul 22 14:12:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507666, encodeId=ea90150e666ba, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Mon Jul 22 14:12:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554206, encodeId=42df155420645, content=<a href='/topic/show?id=ab025182080' target=_blank style='color:#2F92EE;'>#心血管死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51820, encryptionId=ab025182080, topicName=心血管死亡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0fb814514579, createdName=huperzia, createdTime=Mon Jul 22 14:12:00 CST 2019, time=2019-07-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1752209, encodeId=60411e5220941, content=<a href='/topic/show?id=f2188e0859' target=_blank style='color:#2F92EE;'>#Hepcidin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8708, encryptionId=f2188e0859, topicName=Hepcidin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7a536471202, createdName=tm10051993, createdTime=Sat Oct 26 14:12:00 CST 2019, time=2019-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991612, encodeId=0258199161261, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Tue Jul 30 12:12:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783011, encodeId=ff891e83011c1, content=<a href='/topic/show?id=854546080a' target=_blank style='color:#2F92EE;'>#chemistry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4608, encryptionId=854546080a, topicName=chemistry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Thu May 21 20:12:00 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418494, encodeId=7bc5141849464, content=<a href='/topic/show?id=772e5182166' target=_blank style='color:#2F92EE;'>#心血管死亡率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51821, encryptionId=772e5182166, topicName=心血管死亡率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26613379061, createdName=smallant2003, createdTime=Mon Jul 22 14:12:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507032, encodeId=4f9d150e0321b, content=<a href='/topic/show?id=870c9653155' target=_blank style='color:#2F92EE;'>#铁代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96531, encryptionId=870c9653155, topicName=铁代谢)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d84f9850762, createdName=syscxl, createdTime=Mon Jul 22 14:12:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507666, encodeId=ea90150e666ba, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Mon Jul 22 14:12:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554206, encodeId=42df155420645, content=<a href='/topic/show?id=ab025182080' target=_blank style='color:#2F92EE;'>#心血管死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51820, encryptionId=ab025182080, topicName=心血管死亡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0fb814514579, createdName=huperzia, createdTime=Mon Jul 22 14:12:00 CST 2019, time=2019-07-22, status=1, ipAttribution=)]
    2019-07-30 xlxchina
  3. [GetPortalCommentsPageByObjectIdResponse(id=1752209, encodeId=60411e5220941, content=<a href='/topic/show?id=f2188e0859' target=_blank style='color:#2F92EE;'>#Hepcidin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8708, encryptionId=f2188e0859, topicName=Hepcidin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7a536471202, createdName=tm10051993, createdTime=Sat Oct 26 14:12:00 CST 2019, time=2019-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991612, encodeId=0258199161261, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Tue Jul 30 12:12:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783011, encodeId=ff891e83011c1, content=<a href='/topic/show?id=854546080a' target=_blank style='color:#2F92EE;'>#chemistry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4608, encryptionId=854546080a, topicName=chemistry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Thu May 21 20:12:00 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418494, encodeId=7bc5141849464, content=<a href='/topic/show?id=772e5182166' target=_blank style='color:#2F92EE;'>#心血管死亡率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51821, encryptionId=772e5182166, topicName=心血管死亡率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26613379061, createdName=smallant2003, createdTime=Mon Jul 22 14:12:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507032, encodeId=4f9d150e0321b, content=<a href='/topic/show?id=870c9653155' target=_blank style='color:#2F92EE;'>#铁代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96531, encryptionId=870c9653155, topicName=铁代谢)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d84f9850762, createdName=syscxl, createdTime=Mon Jul 22 14:12:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507666, encodeId=ea90150e666ba, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Mon Jul 22 14:12:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554206, encodeId=42df155420645, content=<a href='/topic/show?id=ab025182080' target=_blank style='color:#2F92EE;'>#心血管死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51820, encryptionId=ab025182080, topicName=心血管死亡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0fb814514579, createdName=huperzia, createdTime=Mon Jul 22 14:12:00 CST 2019, time=2019-07-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1752209, encodeId=60411e5220941, content=<a href='/topic/show?id=f2188e0859' target=_blank style='color:#2F92EE;'>#Hepcidin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8708, encryptionId=f2188e0859, topicName=Hepcidin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7a536471202, createdName=tm10051993, createdTime=Sat Oct 26 14:12:00 CST 2019, time=2019-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991612, encodeId=0258199161261, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Tue Jul 30 12:12:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783011, encodeId=ff891e83011c1, content=<a href='/topic/show?id=854546080a' target=_blank style='color:#2F92EE;'>#chemistry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4608, encryptionId=854546080a, topicName=chemistry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Thu May 21 20:12:00 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418494, encodeId=7bc5141849464, content=<a href='/topic/show?id=772e5182166' target=_blank style='color:#2F92EE;'>#心血管死亡率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51821, encryptionId=772e5182166, topicName=心血管死亡率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26613379061, createdName=smallant2003, createdTime=Mon Jul 22 14:12:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507032, encodeId=4f9d150e0321b, content=<a href='/topic/show?id=870c9653155' target=_blank style='color:#2F92EE;'>#铁代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96531, encryptionId=870c9653155, topicName=铁代谢)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d84f9850762, createdName=syscxl, createdTime=Mon Jul 22 14:12:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507666, encodeId=ea90150e666ba, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Mon Jul 22 14:12:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554206, encodeId=42df155420645, content=<a href='/topic/show?id=ab025182080' target=_blank style='color:#2F92EE;'>#心血管死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51820, encryptionId=ab025182080, topicName=心血管死亡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0fb814514579, createdName=huperzia, createdTime=Mon Jul 22 14:12:00 CST 2019, time=2019-07-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1752209, encodeId=60411e5220941, content=<a href='/topic/show?id=f2188e0859' target=_blank style='color:#2F92EE;'>#Hepcidin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8708, encryptionId=f2188e0859, topicName=Hepcidin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7a536471202, createdName=tm10051993, createdTime=Sat Oct 26 14:12:00 CST 2019, time=2019-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991612, encodeId=0258199161261, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Tue Jul 30 12:12:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783011, encodeId=ff891e83011c1, content=<a href='/topic/show?id=854546080a' target=_blank style='color:#2F92EE;'>#chemistry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4608, encryptionId=854546080a, topicName=chemistry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Thu May 21 20:12:00 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418494, encodeId=7bc5141849464, content=<a href='/topic/show?id=772e5182166' target=_blank style='color:#2F92EE;'>#心血管死亡率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51821, encryptionId=772e5182166, topicName=心血管死亡率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26613379061, createdName=smallant2003, createdTime=Mon Jul 22 14:12:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507032, encodeId=4f9d150e0321b, content=<a href='/topic/show?id=870c9653155' target=_blank style='color:#2F92EE;'>#铁代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96531, encryptionId=870c9653155, topicName=铁代谢)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d84f9850762, createdName=syscxl, createdTime=Mon Jul 22 14:12:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507666, encodeId=ea90150e666ba, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Mon Jul 22 14:12:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554206, encodeId=42df155420645, content=<a href='/topic/show?id=ab025182080' target=_blank style='color:#2F92EE;'>#心血管死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51820, encryptionId=ab025182080, topicName=心血管死亡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0fb814514579, createdName=huperzia, createdTime=Mon Jul 22 14:12:00 CST 2019, time=2019-07-22, status=1, ipAttribution=)]
    2019-07-22 syscxl
  6. [GetPortalCommentsPageByObjectIdResponse(id=1752209, encodeId=60411e5220941, content=<a href='/topic/show?id=f2188e0859' target=_blank style='color:#2F92EE;'>#Hepcidin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8708, encryptionId=f2188e0859, topicName=Hepcidin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7a536471202, createdName=tm10051993, createdTime=Sat Oct 26 14:12:00 CST 2019, time=2019-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991612, encodeId=0258199161261, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Tue Jul 30 12:12:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783011, encodeId=ff891e83011c1, content=<a href='/topic/show?id=854546080a' target=_blank style='color:#2F92EE;'>#chemistry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4608, encryptionId=854546080a, topicName=chemistry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Thu May 21 20:12:00 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418494, encodeId=7bc5141849464, content=<a href='/topic/show?id=772e5182166' target=_blank style='color:#2F92EE;'>#心血管死亡率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51821, encryptionId=772e5182166, topicName=心血管死亡率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26613379061, createdName=smallant2003, createdTime=Mon Jul 22 14:12:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507032, encodeId=4f9d150e0321b, content=<a href='/topic/show?id=870c9653155' target=_blank style='color:#2F92EE;'>#铁代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96531, encryptionId=870c9653155, topicName=铁代谢)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d84f9850762, createdName=syscxl, createdTime=Mon Jul 22 14:12:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507666, encodeId=ea90150e666ba, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Mon Jul 22 14:12:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554206, encodeId=42df155420645, content=<a href='/topic/show?id=ab025182080' target=_blank style='color:#2F92EE;'>#心血管死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51820, encryptionId=ab025182080, topicName=心血管死亡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0fb814514579, createdName=huperzia, createdTime=Mon Jul 22 14:12:00 CST 2019, time=2019-07-22, status=1, ipAttribution=)]
    2019-07-22 zll0628
  7. [GetPortalCommentsPageByObjectIdResponse(id=1752209, encodeId=60411e5220941, content=<a href='/topic/show?id=f2188e0859' target=_blank style='color:#2F92EE;'>#Hepcidin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8708, encryptionId=f2188e0859, topicName=Hepcidin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7a536471202, createdName=tm10051993, createdTime=Sat Oct 26 14:12:00 CST 2019, time=2019-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991612, encodeId=0258199161261, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Tue Jul 30 12:12:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783011, encodeId=ff891e83011c1, content=<a href='/topic/show?id=854546080a' target=_blank style='color:#2F92EE;'>#chemistry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4608, encryptionId=854546080a, topicName=chemistry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Thu May 21 20:12:00 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418494, encodeId=7bc5141849464, content=<a href='/topic/show?id=772e5182166' target=_blank style='color:#2F92EE;'>#心血管死亡率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51821, encryptionId=772e5182166, topicName=心血管死亡率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26613379061, createdName=smallant2003, createdTime=Mon Jul 22 14:12:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507032, encodeId=4f9d150e0321b, content=<a href='/topic/show?id=870c9653155' target=_blank style='color:#2F92EE;'>#铁代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96531, encryptionId=870c9653155, topicName=铁代谢)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d84f9850762, createdName=syscxl, createdTime=Mon Jul 22 14:12:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507666, encodeId=ea90150e666ba, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Mon Jul 22 14:12:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554206, encodeId=42df155420645, content=<a href='/topic/show?id=ab025182080' target=_blank style='color:#2F92EE;'>#心血管死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51820, encryptionId=ab025182080, topicName=心血管死亡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0fb814514579, createdName=huperzia, createdTime=Mon Jul 22 14:12:00 CST 2019, time=2019-07-22, status=1, ipAttribution=)]

相关资讯

JACC:血浆脂蛋白水平与缺血性卒中风险呈相关性

高水平的脂蛋白与心梗和主动脉瓣狭窄风险的增加相关,既往研究检测了脂蛋白与卒中发生的相关性,但结果存在矛盾。本研究的目的旨在探究高水平的脂蛋白与缺血性卒中风险的相关性。本研究纳入分析了来自哥本哈根两个临床研究的49699名对象和10813名对象,所有对象的血浆脂蛋白水平都进行了检测。分析结果显示,与血浆脂蛋白93mg/dl的对象的缺血性卒中危险比

肌钙蛋白升高绝不只是心梗!

高敏心肌肌钙蛋白(hs-cTn)目前被公认为心肌梗死诊断中最重要的标志物。然而,很多临床情境下hs-cTn的表达量也会升高,在这些情境中,hs-cTn的升高是否对诊断、预后评估和治疗有指导意义?

JACC:老年低心血管风险的预测因子的探索

心血管疾病风险随着年龄的增加而急剧增加,导致他汀类药物在老年人中的应用非常普遍。为了避免过度治疗,要识别出那些真正心血管病低风险的老年人。本研究的目的旨在找出可以预测老年人短期低冠心病和心血管疾病风险的阴性标志物。本研究纳入分析了5805名研究对象(平均年龄69岁,随访平均时间为2.7年),并对13个候选标志物进行了分析:冠脉钙评分(CAC)=0,CAC≤10,无颈动脉斑块,无家族史,踝臂指数正常

JACC:利妥昔单抗可增加心脏移植术后患者移植物血管病变

CTOT-11临床研究是一项关于心脏移植(HTX)术后患者的多中心随机双盲对照试验,本研究的目的旨在探究B细胞消耗疗法能否减轻心脏移植术后心脏移植血管病变。本研究将163名HTX患者随机分成利妥昔单抗治疗组和安慰剂组,主要终点事件是血管内超声测量的从基线到术后1年动脉粥样硬化体积百分比(PAV)的变化。研究开始时两组患者之间无明显差异,有86名患者在入组时和术后1年接受了血管内超声检测(49名为利

JACC:外科主动脉瓣置换术会减短患者寿命

目前,对于主动脉瓣置换术(AVR)对患者寿命的影响尚不清楚,尤其是对于年轻患者。本研究的目的旨在评估AVR术后远期的生存率和寿命的损失。本研究纳入了SWEDEHEART数据库中1995-2013年接受外科AVR治疗的23528名患者,经过平均6.8年时间的随访,外科AVR术后19年的观察生存率、预期生存率和相对生存率分别为21%, 34%和63%(95% Cl:59%-67%)。整个人群中的平均寿

盘点:JACC七月第一期研究一览

1.更低的社会经济状态能独立预测不良心血管疾病风险